Telmisartan is an angiotensin II receptor blocker (ARB) prescribed for the treatment of hypertension or high blood pressure. It works by blocking the binding of angiotensin II to its receptors, thereby lowering blood pressure by vasodilation and decreasing sodium and water retention. Telmisartan is used alone or in combination with other drugs such as hydrochlorothiazide for better management of hypertension. The global demand for effective antihypertensive drugs is increasing rapidly due to rising prevalence of hypertension worldwide.
The Global Telmisartan Market is estimated to be valued at US$ 4.20 Bn in 2024 and is expected to exhibit a CAGR of 3.7% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Telmisartan market are Boehringer Ingelheim GmbH, Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Mylan N.V., Cipla Ltd., Abbott Laboratories, Cadila Healthcare Ltd, Torrent Pharmaceuticals Ltd., Merck KGaA, Pfizer Inc., Sanofi S.A., Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Macleods Pharmaceuticals Ltd.
Telmisartan Market Growth include increasing awareness about lifestyle diseases, growing geriatric population prone to hypertension, and recent product launches. Technological advancements include development of novel drug delivery systems for improved bioavailability and patient compliance of telmisartan.
Market drivers
The rising cases of hypertension globally is a major market driver. As per WHO, around 1.13 billion people suffered from hypertension in 2019. Growing obese population is another key factor elevating the risks of high blood pressure. Sedentary lifestyle and consumption of junk food have significantly contributed to the obesity pandemic, thereby propelling the need for effective antihypertensive drugs like telmisartan.
Current Challenges in Telmisartan Market
The telmisartan market is facing several challenges currently. The patent expiration of major drugs containing telmisartan has increased generic competition in the market. This has resulted in lower prices and reduced profit margins for major players. Adherence to treatment is also a challenge as telmisartan needs to be taken on a long-term basis to manage blood pressure. This can reduce compliance over time. Furthermore, the side effects of telmisartan like dizziness and headaches may discourage some patients from continuing the treatment.
SWOT Analysis
Strength: Telmisartan is effective in reducing blood pressure and cardiovascular risks. It has a well-established safety profile based on long-term clinical studies.
Weakness: Increased generic competition has impacted prices and profitability. Long-term intake can affect treatment adherence over time.
Opportunity: Growth opportunities exist in emerging markets and improving access in developing nations. New formulations and combination therapies can drive future sales.
Threats: Entry of newer drug alternatives and generic versions pose pricing and market share threats. Stringent regulatory approvals for new indications increase development costs and timeline.
Geographical Regions
North America currently holds the largest share of the global telmisartan market in terms of value owing to growing prevalence of hypertension, developed healthcare infrastructure, and availability of advanced treatment options. Asia Pacific is projected to be the fastest growing regional market for telmisartan during the forecast period driven by rising healthcare spending, increasing disease awareness, and expanding generic drug manufacturing capabilities in major economies.
Rapidly Growing Region
Asia Pacific region is poised to witness the highest CAGR in the global telmisartan market during the forecast period. This is attributed to factors such as rising geriatric population, growing burden of cardiovascular disorders, increasing healthcare access and expenditures, emerging clinical research, and strengthening presence of global drug manufacturers in Asia Pacific countries. China and India are expected to be the major revenue contributors to the Asia Pacific telmisartan market.
Get this Report in Japanese Language:
Get this Report in Korean Language:
Explore More Related Article On- General Anesthesia Drugs Market
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
